Get the Stockscreener App
13.20
3.79%
-0.52
Amneal Pharmaceuticals Inc stock is traded at $13.20, with a volume of 1.50M.
It is down -3.79% in the last 24 hours and up +3.86% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$13.72
Open:
$13.62
24h Volume:
1.50M
Relative Volume:
0.80
Market Cap:
$4.21B
Revenue:
$3.05B
Net Income/Loss:
$181.32M
P/E Ratio:
35.32
EPS:
0.3737
Net Cash Flow:
$225.64M
1W Performance:
+2.88%
1M Performance:
+3.86%
6M Performance:
+16.09%
1Y Performance:
+76.94%
1-Day Range:
$13.12
$13.81
1-Week Range:
$12.65
$13.84
52-Week Range:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.20 | 4.21B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | UBS | Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant - Stock Titan
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares - Stock Titan
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units - Stock Titan
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares - Stock Titan
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX) - Stock Titan
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant - Stock Titan
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant - Stock Titan
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Amneal Pharmaceuticals Q1 2026 & M&A announcement Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition - Stock Titan
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23% - Stock Titan
Amneal (NASDAQ: AMRX) investors back directors, say-on-pay and EY as auditor - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held - Stock Titan
Amneal Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, Vs. FactSet Est of $719.7M - Moomoo
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, Vs. FactSet Est of $0.22 - Moomoo
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Do options traders know something about Amneal stock we don't? - MSN
Number of shareholders of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Vishrut Awasthi Joins Amneal Pharmaceuticals to Lead India Strategy and Business Development - hrtoday.in
Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus - Yahoo Finance
Do Options Traders Know Something About Amneal Stock We Don't? - TradingView
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price Target - Yahoo Finance
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast - Investing.com
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast By Investing.com - Investing.com Canada
AMRX Should I Buy - Intellectia AI
Amneal Pharmaceuticals Q1 2026 earnings preview - MSN
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors - Sahm
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
Artemis Investment Management LLP Buys Shares of 124,899 Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Wall Street analysts see a 34.77% upside in Amneal (AMRX): Can the stock really move this high? - MSN
Amneal (AMRX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings Scheduled For May 1, 2026 - Benzinga
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Amneal Q1 2026 slides: $750M Kashiv deal creates biosimilar leader - Investing.com India
Earnings call transcript: Amneal Pharma Q1 2026 beats EPS forecast By Investing.com - Investing.com India
Amneal (AMRX) Q1 earnings report preview: What to look for - MSN
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge? - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For - StockStory
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):